XML 88 R49.htm IDEA: XBRL DOCUMENT v2.4.0.8
Intangible Assets and Goodwill (Details) (USD $)
 3 Months Ended 9 Months Ended 12 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 3 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2014
Sep. 30, 2013
Sep. 30, 2014
Sep. 30, 2013
Dec. 31, 2013
Sep. 30, 2014
Out-licensed patents
Dec. 31, 2013
Out-licensed patents
Sep. 30, 2014
Out-licensed patents
Minimum
Sep. 30, 2014
Out-licensed patents
Maximum
Sep. 30, 2014
Developed technology
Dec. 31, 2013
Developed technology
Sep. 30, 2014
Developed technology
Minimum
Sep. 30, 2014
Developed technology
Maximum
Sep. 30, 2014
Developed technology
AVONEX
Sep. 30, 2014
Acquired and in-licensed rights and patents
Dec. 31, 2013
Acquired and in-licensed rights and patents
Sep. 30, 2014
Acquired and in-licensed rights and patents
Minimum
Sep. 30, 2014
Acquired and in-licensed rights and patents
Maximum
Sep. 30, 2014
In-process research and development
Sep. 30, 2014
In-process research and development
Dec. 31, 2013
In-process research and development
Sep. 30, 2014
Trademarks and trade names
Dec. 31, 2013
Trademarks and trade names
Apr. 02, 2013
TYSABRI product
Sep. 30, 2014
TYSABRI product
Acquired and in-licensed rights and patents
Sep. 30, 2014
ALPROLIX product
Sep. 30, 2014
ALPROLIX product
Acquired and in-licensed rights and patents
Sep. 30, 2014
Fumapharm AG
TECFIDERA
Sep. 30, 2014
Two billion
Fumapharm AG
Jun. 30, 2014
Two billion
Fumapharm AG
Sep. 30, 2014
Two billion
Fumapharm AG
TECFIDERA
Sep. 30, 2014
Three billion
Fumapharm AG
Sep. 30, 2014
Three billion
Fumapharm AG
TECFIDERA
Intangible assets                                                                  
Estimated life, (in years)               13 years 23 years     15 years 23 years       6 years 17 years                              
Indefinite lived intangible assets useful life                                       Indefinite until commercialization   Indefinite                      
Cost           $ 543,300,000 $ 578,000,000     $ 3,005,300,000 $ 3,005,300,000       $ 3,274,400,000 $ 3,240,000,000                                  
Cost and Net                                     314,100,000 314,100,000 327,400,000 64,000,000 64,000,000                    
Total intangible assets, gross 7,201,100,000   7,201,100,000   7,214,700,000                                                        
Accumulated Amortization (3,071,300,000)   (3,071,300,000)   (2,740,000,000) (473,800,000) (450,800,000)     (2,339,800,000) (2,165,400,000)       (257,700,000) (123,800,000)     0 0 0 0 0                    
Net           69,500,000 127,200,000     665,500,000 839,900,000     656,000,000 3,016,700,000 3,116,200,000                 2,957,400,000                
Intangible assets, net 4,129,754,000   4,129,754,000   4,474,653,000                                                        
Impairment of in-process research and development asset                                     16,200,000                            
Total impairment charges     50,900,000                                                            
Impairment of out-licensed patent           34,700,000                                                      
Changes in fair value 49,433,000 97,000 46,213,000 2,983,000                             (49,400,000)                            
Net intangible asset                                               3,178,300,000                  
Contingent payment                                                   20,000,000              
Increase in in-licensed rights and patents                                                     7,800,000            
Income tax benefit (expense) 274,774,000 186,105,000 721,709,000 410,753,000                                               41,700,000          
Intangible Assets and Goodwill (Textual) [Abstract]                                                                  
Amortization of acquired intangible assets 122,431,000 99,998,000 382,515,000 233,524,000                                                          
Increase to goodwill     308,300,000   35,700,000                                             350,000,000     150,000,000   200,000,000
Cumulative sales level                                                         2,000,000,000 2,000,000,000   3,000,000,000  
Accumulated impairment losses related to goodwill 0   0                                                            
Intangible Assets And Goodwill (Additional Textual) [Abstract]                                                                  
Expected future amortization expense, 2014 (remaining three months) 104,200,000   104,200,000                                                            
Expected future amortization expense, 2015 345,200,000   345,200,000                                                            
Expected future amortization expense, 2016 309,500,000   309,500,000                                                            
Expected future amortization expense, 2017 285,500,000   285,500,000                                                            
Expected future amortization expense, 2018 284,500,000   284,500,000                                                            
Expected future amortization expense, 2019 273,300,000   273,300,000                                                            
Total $ 1,602,200,000   $ 1,602,200,000